PTN 241115 7.50C (PTN241115C7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

PTN241115C7500

Watchlist

0.00
0.000.00%

15min DelayClose Oct 31 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Palatin Technologies Inc - Topline Results Expected in 1Q 2025
ReutersOct 31 07:30 ET
Express News | Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (Mc4R Agonist) Co-Administered With Tirzepatide (GLP-1/Gip) for the Treatment of Obesity
ReutersOct 31 07:30 ET
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
PR NewswireOct 31 07:30 ET
Innovative Breakthroughs in Obesity Treatment Position Palatin Technologies for Market Success
TipRanksOct 23 08:45 ET
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
PR NewswireOct 23 07:30 ET
12 Health Care Stocks Moving In Monday's After-Market Session
BenzingaOct 14 16:31 ET

Comments

Jaguar8

Yesterday 19:35

NEWS

$Palatin Technologies (PTN.US)$
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
• Topline results expected in 1Q calendar year 2025
• Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight
• Data will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compoun...

Happy me

Oct 29 11:19

$Palatin Technologies (PTN.US)$ so Happy buying $1.17 bottom of the year . look cheap to Happy Me .. squeezing call it 😃👍💎✅🚀

Stock_Drift

Oct 24 10:33

😃🎃🎯💚

$Palatin Technologies (PTN.US)$

Jaguar8

Oct 1 06:32

NEWS

$Palatin Technologies (PTN.US)$
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
• Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)
◦ Patient Dosing Commenced 3Q Calendar Year 2024
◦ Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024
◦ Topline Results Expected 1Q Calendar Year 2025
• Dry Eye...

Trytosaveabit

Sep 9 06:33

Update

$Palatin Technologies (PTN.US)$ Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
3 MINUTES AGO, 7:30 AM EDT
VIA PR NEWSWIRE
Dry Eye Disease (DED): PL9643
◦ MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies
▪ FDA Confirms Protocols and Endpoints
▪ Targeting Enrollment Start in 4Q Calendar Year 2024
▪ Topline Results Anticipated 4Q Calendar Year 2025
◦ Potential Collaboration/Funding Discussions Ongoing
• Obesity: Phase 2 Clinical Study ...